OncoCyte Corporation OCX
Set alert
At close · Jun 17
52-week range unavailable
- YTD
- +34.45%
- 1 year
- +15.94%
- Open
- 2.82
- Prev close
- 3.20
- Mkt cap
- 36.87M
- Vol
- 100.56K
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 2.82
- High
- 3.20
- Forward P/E
- -1.27
- Beta
- 0.00
- Short ratio
- 2.59
- Inst. own
- 50.60%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Mar 29, 2024
- 50-d avg
- 2.73
- 200-d avg
- 2.89
- 1y target
- 4.13
Key statistics
- Market cap
- 36.87M
- Enterprise value
- 30.66M
- Trailing P/E
- 0.00
- Forward P/E
- -1.27
- PEG ratio
- 0.00
- Price / sales
- 52.00
- Price / book
- 3.09
- EPS (TTM)
- -4.44
- Beta
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 709.00K
- Revenue growth
- -73.20%
- Free cash flow
- -7.61M
- Total cash
- 3.36M
- Total debt
- 3.99M
- Return on equity
- -165.32%
- Shares outstanding
- 16.84M
- Short % of float
- 1.88%
- 50-day average
- 2.73
- 200-day average
- 2.89
Analyst view
Consensus: none
- Target (low)
- 4.00
- Target (mean)
- 4.13
- Target (high)
- 4.25
- Strong buy1
- Buy0
- Hold2
- Sell0
- Strong sell0
Next earnings
Mar 29, 2024
Expected Mar 29, 2024. Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 12, 2024 | Sep 1, 2024 | 0.00 | -0.98 | — | — |
| Aug 8, 2024 | Jun 1, 2024 | 0.00 | -0.36 | — | — |
| May 15, 2024 | Mar 1, 2024 | 0.00 | -1.13 | — | — |
| Mar 29, 2024 | Dec 1, 2023 | -1.57 | — | — | — |
| Nov 9, 2023 | Sep 1, 2023 | -1.52 | -0.57 | +0.95 | +62.50% |
| Aug 10, 2023 | Jun 1, 2023 | -2.60 | -1.07 | +1.53 | +58.85% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 9, 2024 | Needham | reit | Buy | Buy |
| May 16, 2024 | Needham | reit | Buy | Buy |
| Apr 24, 2024 | Needham | main | Buy | Buy |
| Apr 17, 2024 | Stephens & Co. | reit | Equal-Weight | Equal-Weight |
| Apr 15, 2024 | Benchmark | reit | Speculative Buy | Speculative Buy |
| Nov 13, 2023 | Piper Sandler | main | Neutral | Neutral |
About OncoCyte Corporation
OncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test. It also provides testing services for biomarker discovery, assay design and development, clinical trial support, and various biomarker tests. The company has a collaboration agreement with Bio-Rad Laboratories, Inc. (Bio-Rad) to collaborate in the development and the commercialization of research use only and in vitro diagnostics kitted transplant products using Bio-Rad's ddPCR instruments and reagents. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Country
- United States
- Website
- oncocyte.com
News
- Oncocyte Eyes Faster, Less Invasive Heart Transplant Rejection Testing
- Oncocyte Q2 Earnings Call Highlights
- Oncocyte Changes Name to Insight Molecular Diagnostics Inc. (iMDx), Moves Headquarters to Nashville
- Medicare Boosts Reimbursement for Oncocyte's Flagship Technology
- OncoCyte Corporation (OCX) Q1 2025 Earnings Call Transcript
- Oncocyte Reports Q1 2025 Results and Business Progress
- Earnings Scheduled For May 12, 2025
- Oncocyte to Release First Quarter 2025 Results on May 12, 2025
- Oncocyte to Release First Quarter 2025 Results on May 12, 2025
- Best Momentum Stocks to Buy for May 6th
Your note
Sign in to keep a note on OCX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ARNO ANDREW | Director | Purchase | Apr 10, 2024 | 84,662 |
| BROADWOOD PARTNERS, L.P. | Beneficial Owner of more than 10% of a Class of Security | Purchase | Oct 1, 2024 | 0 |
| GUTFREUND JOHN PETER | Director | Stock Award(Grant) | Apr 2, 2023 | 0 |
| JAMES ANDREA S. | Chief Financial Officer | Purchase | Dec 4, 2024 | 53,670 |
| KINGSLEY ALFRED D | Director | Stock Award(Grant) | Jun 22, 2023 | 583,223 |
| LAST ANDREW J | Director | Stock Award(Grant) | Jun 22, 2023 | 90,170 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Broadwood Capital, Inc. | 29.28% | 4,929,066 | 10.79M | Sep 29, 2024 |
| AWM Investment Company, Inc. | 6.52% | 1,097,175 | 2.40M | Sep 29, 2024 |
| Pura Vida Investments, Llc | 2.94% | 495,345 | 1.08M | Sep 29, 2024 |
| Vanguard Group Inc | 1.46% | 245,388 | 537.40K | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.62% | 103,980 | 227.72K | Sep 29, 2024 |
| Blackrock Inc. | 0.47% | 79,833 | 174.83K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 0.92% | 154,885 | 339.20K | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 0.50% | 84,999 | 186.15K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.40% | 67,344 | 147.48K | Oct 30, 2024 |
| iShares Micro Cap ETF | 0.11% | 18,032 | 39.49K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.09% | 14,756 | 32.31K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.08% | 13,836 | 30.30K | Oct 30, 2024 |